Currently it is unclear if at risk patient groups respond to COVID-19 vaccination, has adverse risk of toxicity or a blunting of vaccine efficacy. We are in a unique position to assess this as we will collect blood samples from a well defined cohort of subjects with an established diagnosis of a disease causing single gene defect that will be imminently offered the vaccine. We will compare this with immunotherapy treated patients. We will quantitatively measure adaptive immunity pre- and post- vaccination in these subjects and assess the correlation of this with either vaccine adverse effects or vaccine efficacy.
